Retatrutide Pharmacogenetics: Triple Agonist Genetics (Investigational)

Retatrutide (Eli Lilly, development code LY3437943) is an investigational triple agonist that hits three receptors at once: GLP-1, GIP, and glucagon. Phase 2 trial data showed about 24 percent body weight loss at 48 weeks, exceeding any approved incretin agent. The drug is currently in phase 3 trials and is not yet FDA-approved.

When to Seek Immediate Help

Retatrutide is investigational. Adverse events should be reported through your clinical trial team or to the FDA MedWatch program. Severe abdominal pain, persistent vomiting, or signs of pancreatitis warrant immediate medical attention.

Common Reasons This Can Happen

Why a third receptor matters

Glucagon receptor activation increases energy expenditure, complementing the appetite-reducing effects of GLP-1 and GIP activation. The combination is what drives the larger weight loss seen in trials.

Why pharmacogenetic data is preliminary

Most retatrutide pharmacogenetic guidance is extrapolated from semaglutide and tirzepatide research because those drugs share the GLP-1 and GIP arms. Direct retatrutide pharmacogenetic data is expected as the phase 3 program reads out.

Could Your Genetics Be a Factor?

Three genes encode the three receptors retatrutide activates. Two have well-characterized pharmacogenetic signals from related drugs; the third is an open question.

GLP1R

The Pro7Leu variant (rs10305420) affects all GLP-1 agonists, including retatrutide. Leu7 carriers are expected to have slightly greater weight loss and modestly higher nausea risk from the GLP-1 arm of retatrutide.

GIPR

The Gln354 variant (rs1800437) reduces GIP-receptor function. By analogy with tirzepatide, Gln354 carriers are expected to have higher GI side-effect risk on retatrutide. Direct retatrutide data is not yet available.

GCGR

The glucagon receptor adds the third arm of activity. No common GCGR variant has been shown to substantially alter retatrutide response in published data so far. Active research area.

The strongest pharmacogenetic signal expected for retatrutide is the GIPR Gln354 effect on GI side effects. The GLP1R signal-peptide effect should also carry over. The GCGR component contributes additional weight loss beyond what dual agonists achieve, but no actionable common variant has been identified for it yet.

When to Consider Pharmacogenetic Testing

Most relevant if you are enrolled in or considering enrollment in a retatrutide trial, or if you are weighing whether GIPR-mediated nausea on tirzepatide makes retatrutide a poor fit when it becomes available.

What You Can Do Next

If you are in a retatrutide trial, share your GIPR genotype with your study team. Trial protocols will not adjust dose based on genetics, but the information helps set expectations.
If you have struggled with tirzepatide nausea and you carry the GIPR variant, consider that the same effect is likely on retatrutide once it is approved.
Track the literature. As phase 3 results are published, retatrutide-specific pharmacogenetic data will become available.

Related Medications

Learn how genetics may affect your response to these related medications:

Related Guides

Frequently Asked Questions

When will retatrutide be available?

Lilly expects to file for FDA approval based on the ongoing phase 3 program. Timing of approval depends on trial readouts and FDA review. Until approval, the drug is available only through clinical trials.

Will retatrutide be better than tirzepatide?

Phase 2 data showed greater weight loss for retatrutide than tirzepatide at the highest doses. The phase 3 data will be more authoritative, but the early signal is positive.

Will retatrutide have new pharmacogenetic concerns from the glucagon arm?

Possibly, though so far no common GCGR variant has been linked to a meaningful clinical difference. The glucagon arm increases energy expenditure, and theoretical effects on baseline glucose handling are being watched in trials.

Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making changes to your medication. Never stop or change medication without medical supervision.